The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms.
Level 5 - mechanism / opinion, no new human data
Clinical practice guideline and expert consensus synthesizing existing literature without new empirical human trial data.
PubMed 35152405 · doi:10.1002/cpt.2557
What was done
The Clinical Pharmacogenetics Implementation Consortium (CPIC) reviewed published literature evaluating associations between genetic variants in SLCO1B1 (hepatic uptake transporter), ABCG2 (efflux transporter), and CYP2C9 (phase I metabolizing enzyme) and systemic exposure or statin-associated musculoskeletal symptoms (SAMS) across multiple statins. The panel developed updated clinical recommendations for genotype-guided statin selection and dosing, replacing prior 2012 and 2014 guidelines.
What was found
The abstract reports no numerical data, effect sizes, or study counts. It qualitatively notes that genetic variation in SLCO1B1, ABCG2, and CYP2C9 alters systemic exposure to simvastatin, rosuvastatin, pravastatin, pitavastatin, atorvastatin, fluvastatin, and lovastatin, which can increase the risk for SAMS, and provides therapeutic recommendations based on these genotypes.
Why it matters
This guideline broadens genotype-guided statin therapy beyond the initial SLCO1B1-simvastatin association to include ABCG2 and CYP2C9 across seven statins, assisting clinicians in minimizing adverse muscular effects and improving statin adherence.
Limits
The abstract contains no quantitative metrics, trial counts, or sample sizes. Recommendations reflect expert consensus synthesis of published literature rather than a new primary empirical investigation, and clinical impact depends on the availability and implementation of pharmacogenetic testing.
Cited by
- supports Genetic testing can identify individual susceptibility to statin-induced myopathy and muscle damage.